‹ All Posts
Tejaswi

5 mins ago · SEBI Registration INA200015176

Entero Healthcare: Revenue Up 32.9%, PAT Up 66%

ENTERO Entero Healthcare Solutions (NSE : ENTERO) is a Mumbai-based healthcare distributor. It supplies pharmaceuticals, medical devices, OTC products and vaccines to over 92,200 retail pharmacies and 2,900 hospitals across 499 districts. Its MedTech vertical covers cardiology, orthopaedics, diagnostics and imaging devices. What happened: In Q2 FY27, revenue grew 32.9% year on year to Rs 2,087.1 crore. Organic revenue grew 18.2% year on year and 20% on a like-for-like basis. Gross profit rose 49% to Rs 240 crore, with gross margin expanding 126 bps to 11.5%. EBITDA grew 78% to Rs 110.7 crore, with EBITDA margin rising 135 bps to 5.3%. Net profit grew 66% to Rs 60.7 crore. Why it matters: Organised distributors account for only 8-10% of India’s pharmaceutical distribution market, compared with over 90% in the US. Management shed low-margin accounts during the period, which helped margins expand even as revenue scaled. MedTech revenue is expected to exceed Rs 1,000 crore in FY27, up from roughly Rs 600 crore in H1. Debt repayment begins in Q3 FY27, which will reduce interest costs and improve profit attributable to equity owners. What I am watching: Whether margin expansion holds as Entero continues adding distribution clients. Management has guided for 23% revenue growth in FY27, an EBITDA margin of 5% and conversion of 50% of EBITDA into operating cash flow. My stance: Entero trades at 60 times earnings, above its 2.5-year historical median of 55.7 times and the industry median of 45.2 times. ROCE is 22.0% and ROE is 22.4%, well above industry averages. The premium is justified only if margin expansion continues alongside strong revenue growth. I do not hold a position in Entero Healthcare Solutions at the time of writing. This is not investment advice.

#HiddenGems#TrendingSectors#FundamentalViews#EquityResearch
1 like